Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TY-1091 in RET-altered advanced solid tumors
CTR20223304Phase 2Active
- Sponsor
- TYK Medicines
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TY-1091 in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC) and Nonhematologic neoplasms (2 arms), sponsored by TYK Medicines. Primary endpoints: Dose-limiting toxicity and overall safety in dose-escalation and Objective response rate in expansion. Started Apr 2023; status: active.
02
Drugs
TY-1091
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20223304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223304.